Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...
The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback